Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone626-304-3400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.14 million
Profitability
Miscellaneous
Employees116
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions
What is Arrowhead Pharmaceuticals' stock symbol?
Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."
How were Arrowhead Pharmaceuticals' earnings last quarter?
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) issued its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.02. The biotechnology company earned $48.15 million during the quarter, compared to analyst estimates of $45.78 million. Arrowhead Pharmaceuticals had a return on equity of 6.72% and a net margin of 10.09%. View Arrowhead Pharmaceuticals' Earnings History.
When is Arrowhead Pharmaceuticals' next earnings date?
What price target have analysts set for ARWR?
6 analysts have issued 12-month price targets for Arrowhead Pharmaceuticals' stock. Their predictions range from $11.68 to $33.00. On average, they anticipate Arrowhead Pharmaceuticals' stock price to reach $23.8633 in the next twelve months. This suggests that the stock has a possible downside of 0.7%. View Analyst Price Targets for Arrowhead Pharmaceuticals.
What is the consensus analysts' recommendation for Arrowhead Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arrowhead Pharmaceuticals.
Has Arrowhead Pharmaceuticals been receiving favorable news coverage?
Media stories about ARWR stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Arrowhead Pharmaceuticals' key competitors?
Some companies that are related to Arrowhead Pharmaceuticals include Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO), Marina Biotech (MRNA), Catalent (CTLT), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Array Biopharma (ARRY) and Nektar Therapeutics (NKTR).
What other stocks do shareholders of Arrowhead Pharmaceuticals own?
Who are Arrowhead Pharmaceuticals' key executives?
Arrowhead Pharmaceuticals' management team includes the folowing people:
- Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 50)
- Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 53)
- Dr. Bruce D. Given, Chief Operating Officer (Age 65)
- Mr. Patrick O'Brien, Gen. Counsel (Age 55)
- Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando
Who are Arrowhead Pharmaceuticals' major shareholders?
Arrowhead Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include OppenheimerFunds Inc. (8.28%), BlackRock Inc. (8.10%), First Manhattan Co. (5.23%), FMR LLC (1.81%), Fiera Capital Corp (1.65%) and Goldman Sachs Group Inc. (1.32%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.
Which major investors are selling Arrowhead Pharmaceuticals stock?
ARWR stock was sold by a variety of institutional investors in the last quarter, including Hsbc Holdings PLC, First Trust Advisors LP, First Manhattan Co., Goldman Sachs Group Inc., 361 Capital LLC, Blair William & Co. IL, Fiera Capital Corp and FMR LLC. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
Which major investors are buying Arrowhead Pharmaceuticals stock?
ARWR stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Geode Capital Management LLC, Charles Schwab Investment Management Inc., JPMorgan Chase & Co., Northern Trust Corp, AQR Capital Management LLC and Morgan Stanley. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
How do I buy shares of Arrowhead Pharmaceuticals?
Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arrowhead Pharmaceuticals' stock price today?
One share of ARWR stock can currently be purchased for approximately $24.04.
How big of a company is Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals has a market capitalization of $2.28 billion and generates $16.14 million in revenue each year. The biotechnology company earns $-54,450,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.
What is Arrowhead Pharmaceuticals' official website?
How can I contact Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]
MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.
